First-in-Human ²¹²Pb-PSMA-Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer

J Nucl Med. 2024 Apr 1;65(4):664. doi: 10.2967/jnumed.123.267189.

Affiliations

¹ Department of Nuclear Medicine and Specialist PET Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
² AdvanCell, Sydney, New South Wales, Australia; and.
³ Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
⁴ AdvanCell, Sydney, New South Wales, Australia; and stephen@advancell.com.au.

No abstract available

MeSH terms

Humans
Lead*
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant* / diagnostic imaging
Prostatic Neoplasms, Castration-Resistant* / pathology
Prostatic Neoplasms, Castration-Resistant* / radiotherapy
Radiopharmaceuticals
Single Photon Emission Computed Tomography Computed Tomography

Substances

Lead
Prostate-Specific Antigen
Radiopharmaceuticals